Jonathan Q Purnell1, Elizabeth N Dewey2, Blandine Laferrère3, Faith Selzer4, David R Flum5, James E Mitchell6, Alfons Pomp7, Walter J Pories8, Thomas Inge9, Anita Courcoulas10, Bruce M Wolfe2. 1. Department of Medicine, Oregon Health & Science University, Portland, OR, USA. 2. Department of Surgery, Oregon Health & Science University, Portland, OR, USA. 3. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. 4. Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Department of Surgery, University of Washington, Seattle, WA, USA. 6. Department of Clinical Neuroscience, University of North Dakota, Fargo, ND, USA. 7. Department of Surgery, Weill Cornell Medical College, New York, NY, USA. 8. Department of Surgery, East Carolina University, Greenville, NC, USA. 9. Department of Surgery, University of Colorado, Denver, CO, USA. 10. Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
CONTEXT: Few studies have examined the clinical characteristics that predict durable, long-term diabetes remission after bariatric surgery. OBJECTIVE: To compare diabetes prevalence and remission rates during 7-year follow-up after Roux-en-Y gastric bypass (RYGB) and laparoscopic gastric banding (LAGB). DESIGN: An observational cohort of adults with severe obesity recruited between 2006 and 2009 who completed annual research assessments for up to 7 years after RYGB or LAGB. SETTING: Ten US hospitals. PARTICIPANTS: A total sample of 2256 participants, 827 with known diabetes status at both baseline and at least 1 follow-up visit. INTERVENTIONS: Roux-en-Y gastric bypass or LAGB. MAIN OUTCOME MEASURES: Diabetes rates and associations of patient characteristics with remission status. RESULTS: Diabetes remission occurred in 57% (46% complete, 11% partial) after RYGB and 22.5% (16.9% complete, 5.6% partial) after LAGB. Following both procedures, remission was greater in younger participants and those with shorter diabetes duration, higher C-peptide levels, higher homeostatic model assessment of β-cell function (HOMA %B), and lower insulin usage at baseline, and with greater postsurgical weight loss. After LAGB, reduced HOMA insulin resistance (IR) was associated with a greater likelihood of diabetes remission, whereas increased HOMA-%B predicted remission after RYGB. Controlling for weight lost, diabetes remission remained nearly 4-fold higher compared with LAGB. CONCLUSIONS: Durable, long-term diabetes remission following bariatric surgery is more likely when performed soon after diagnosis when diabetes medication burden is low and beta-cell function is preserved. A greater weight-independent likelihood of diabetes remission after RYGB than LAGB suggests mechanisms beyond weight loss contribute to improved beta-cell function after RYGB.Trial Registration clinicaltrials.gov Identifier: NCT00465829.
CONTEXT: Few studies have examined the clinical characteristics that predict durable, long-term diabetes remission after bariatric surgery. OBJECTIVE: To compare diabetes prevalence and remission rates during 7-year follow-up after Roux-en-Y gastric bypass (RYGB) and laparoscopic gastric banding (LAGB). DESIGN: An observational cohort of adults with severe obesity recruited between 2006 and 2009 who completed annual research assessments for up to 7 years after RYGB or LAGB. SETTING: Ten US hospitals. PARTICIPANTS: A total sample of 2256 participants, 827 with known diabetes status at both baseline and at least 1 follow-up visit. INTERVENTIONS: Roux-en-Y gastric bypass or LAGB. MAIN OUTCOME MEASURES: Diabetes rates and associations of patient characteristics with remission status. RESULTS: Diabetes remission occurred in 57% (46% complete, 11% partial) after RYGB and 22.5% (16.9% complete, 5.6% partial) after LAGB. Following both procedures, remission was greater in younger participants and those with shorter diabetes duration, higher C-peptide levels, higher homeostatic model assessment of β-cell function (HOMA %B), and lower insulin usage at baseline, and with greater postsurgical weight loss. After LAGB, reduced HOMA insulin resistance (IR) was associated with a greater likelihood of diabetes remission, whereas increased HOMA-%B predicted remission after RYGB. Controlling for weight lost, diabetes remission remained nearly 4-fold higher compared with LAGB. CONCLUSIONS: Durable, long-term diabetes remission following bariatric surgery is more likely when performed soon after diagnosis when diabetes medication burden is low and beta-cell function is preserved. A greater weight-independent likelihood of diabetes remission after RYGB than LAGB suggests mechanisms beyond weight loss contribute to improved beta-cell function after RYGB.Trial Registration clinicaltrials.gov Identifier: NCT00465829.
Authors: Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski Journal: N Engl J Med Date: 2013-06-24 Impact factor: 91.245
Authors: M Nannipieri; A Mari; M Anselmino; S Baldi; E Barsotti; D Guarino; S Camastra; R Bellini; R D Berta; E Ferrannini Journal: J Clin Endocrinol Metab Date: 2011-07-21 Impact factor: 5.958
Authors: Matthew L Maciejewski; David E Arterburn; Lynn Van Scoyoc; Valerie A Smith; William S Yancy; Hollis J Weidenbacher; Edward H Livingston; Maren K Olsen Journal: JAMA Surg Date: 2016-11-01 Impact factor: 14.766
Authors: John B Dixon; Paul E O'Brien; Julie Playfair; Leon Chapman; Linda M Schachter; Stewart Skinner; Joseph Proietto; Michael Bailey; Margaret Anderson Journal: JAMA Date: 2008-01-23 Impact factor: 56.272
Authors: Geltrude Mingrone; Simona Panunzi; Andrea De Gaetano; Caterina Guidone; Amerigo Iaconelli; Giuseppe Nanni; Marco Castagneto; Stefan Bornstein; Francesco Rubino Journal: Lancet Date: 2015-09-05 Impact factor: 79.321
Authors: Mihoko Yoshino; Brandon D Kayser; Jun Yoshino; Richard I Stein; Dominic Reeds; J Christopher Eagon; Shaina R Eckhouse; Jeramie D Watrous; Mohit Jain; Rob Knight; Kenneth Schechtman; Bruce W Patterson; Samuel Klein Journal: N Engl J Med Date: 2020-08-20 Impact factor: 91.245
Authors: Veeradej Pisprasert; Katherine H Ingram; Maria F Lopez-Davila; A Julian Munoz; W Timothy Garvey Journal: Diabetes Care Date: 2012-12-06 Impact factor: 19.112
Authors: Margaret S Bohm; Laura M Sipe; Madeline E Pye; Matthew J Davis; Joseph F Pierre; Liza Makowski Journal: Cancer Metastasis Rev Date: 2022-07-23 Impact factor: 9.237